Open Access
Subscription or Fee Access
Novel plasma therapy for covid-19: A Perspective
Abstract
Coronavirus disease (COVID-19) is an induced disease caused by the coronavirus-19 that causes acute respiratory syndrome (SARS COVID-19). In the month of December 2019, the first case was recorded in Wuhan, China. No specific medications have yet been approved for their treatment; convalescent plasma therapy is projected to boost the survival rate. Early in the twentieth century, convalescent plasma therapy was developed. Convalescent plasma therapy is widely utilized around the world, and it has proven to be effective in saving the lives of COVID-19 patients. Convalescent plasma containing antibodies capable of neutralizing SARS-CoV-2 has shown potential in preventing viral replication and relieving patients' clinical symptoms in preliminary investigations. To definitively elucidate the safety and efficacy of this blood component in COVID-19, the findings of numerous ongoing randomized controlled trials are eagerly awaited. The current evidence from the literature on the treatment of serve COVID-19 with convalescent plasma is summarized in this narrative review.
Keywords
References
C.G. Chidume, C.N. Oko-Otu, G.C. Aro, State Fragility and COVID-19 pandemic Implications on the political economy of Nigeria, Social Sciences & Humanities Open, 2021:3(1), 2021:100127.
M. Keikha, M. Karbalaei, Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study, New Microbes and New Infections, New Microbes New Infect. 2021 Jul; 42:100901.
Knudson CM, Jackson JB. 6 May 2020. COVID-19 convalescent plasma:phase 2. Transfusion. 2020 Jun; 60(6):1332-1333.
Madariaga MLL, Guthmiller J, Schrantz S, Jansen M, Christenson C, Kumar M, Prochaska M, Wool G, Durkin A, Oh WH, Trockman L, Vigneswaran JKeskey R, Shaw DG, Dugan H, Zheng N, Cobb M, Utset H, Wang J, StovicekO, Bethel C, Matushek S, Giurcanu M, Beavis K, diSabato D, Meltzer D Ferguson M, Kress JP, Shanmugarajah K, Matthews J, Fung J, Wilson P, JC, Donington J. 2020. Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2021 Apr; 289(4):559-573.
Robbiani DF, Gaebler C, Muecksch F, CetruloLorenzi J, Wang Z, Cho A, Agudelo M, Barnes C, Finkin S, Hagglof T, Oliveira T, Viant C, Hurley A,Millard K, Kost R, Cipolla M, Gazumyan A, Gordon K, Bianchini F, ChenS, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Hoffmann H-H,Michailidis E, Ashbrook A, Waltari EF, Pak J, Huey-Tubman K, KorandaN, Hoffman P, West A, Rice C, Hatziioannou T, Bjorkman P, Bieniasz P, Caskey M, Nussenzweig M. 2020. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. Nature. 2020 Aug; 584(7821): 437-442.
Tiberghien P, de Lambalerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how. Vox Sang. 2020; 115(6):488–494.
Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020; 323(16):1561–1562.
Smid WM, Burnouf T, Epstein J, et al. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low-and middle-income countries. Available online at: https://www.isbtweb.org/fileadmin/user_upload/FINAL_Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_in_LMIC.pdf
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1): 1-22.
Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr; 92(4):418-423.
Tanne JH. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020; 368:m1256.
C Shen, Z Wang, F Zhao, et al. Treatment of 5 Critically Ill Patients with COVID-19 Convalescent Plasma. JAMA. 2020 Apr 28; 323(16):1582-1589.
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020; 117(17):9490–9496.
Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis.2020; 222(1): Pages 38–43.
Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562.
DOI: https://doi.org/10.37591/rrjooh.v10i3.2724
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: Journal of Oncology and Hematology